These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 23999768)

  • 1. Adverse event profile and dose modification of everolimus for advanced renal cell carcinoma in real-world Japanese clinical practice.
    Nozawa M; Nonomura N; Ueda T; Nishimura K; Kanayama HO; Miki T; Nakatani T; Tomita Y; Azuma H; Yoshioka T; Tsujihata M; Uemura H
    Jpn J Clin Oncol; 2013 Nov; 43(11):1132-8. PubMed ID: 23999768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III trial of everolimus in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from RECORD-1.
    Tsukamoto T; Shinohara N; Tsuchiya N; Hamamoto Y; Maruoka M; Fujimoto H; Niwakawa M; Uemura H; Usami M; Terai A; Kanayama HO; Sumiyoshi Y; Eto M; Akaza H
    Jpn J Clin Oncol; 2011 Jan; 41(1):17-24. PubMed ID: 20965941
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experience with everolimus therapy for patients with metastatic renal cancer in Hungary].
    Maráz A; Bodoky G; Dank M; Géczi L; Kahán Z; Mangel L; Révész J; Szűcs M
    Magy Onkol; 2014 Mar; 58(1):4-9. PubMed ID: 24712001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of the safety and efficacy of temsirolimus in East Asian patients with advanced renal cell carcinoma.
    Sun Y; Rha S; Lee SH; Guo J; Ueda T; Qin S; Naito S; Cincotta M; Tokushige K; Akaza H
    Jpn J Clin Oncol; 2012 Sep; 42(9):836-44. PubMed ID: 22844126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of interstitial lung disease during everolimus treatment in patients with metastatic renal cell carcinoma.
    Mizuno R; Asano K; Mikami S; Nagata H; Kaneko G; Oya M
    Jpn J Clin Oncol; 2012 May; 42(5):442-6. PubMed ID: 22438405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
    Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
    Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program.
    van den Eertwegh AJ; Karakiewicz P; Bavbek S; Rha SY; Bracarda S; Bahl A; Ou YC; Kim D; Panneerselvam A; Anak O; Grünwald V
    Urology; 2013 Jan; 81(1):143-9. PubMed ID: 23273080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma.
    Nozawa M; Ohzeki T; Tamada S; Hongo F; Anai S; Fujimoto K; Miki T; Nakatani T; Fukasawa S; Uemura H
    Int J Clin Oncol; 2015 Aug; 20(4):790-5. PubMed ID: 25342378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of pneumocystis pneumonia associated with everolimus therapy for renal cell carcinoma.
    Saito Y; Nagayama M; Miura Y; Ogushi S; Suzuki Y; Noro R; Minegishi Y; Kimura G; Kondo Y; Gemma A
    Jpn J Clin Oncol; 2013 May; 43(5):559-62. PubMed ID: 23423809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two cases of everolimus-associated interstitial pneumonia in patients with renal cell carcinoma.
    Akata K; Yatera K; Ishimoto H; Kozaki M; Yamasaki K; Nagata S; Nishida C; Yoshida T; Kawanami T; Matsumoto T; Mukae H
    Intern Med; 2011; 50(24):3013-7. PubMed ID: 22185995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of sequential use of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trial.
    Oyama M; Sugiyama T; Nozawa M; Fujimoto K; Kishida T; Kimura G; Tokuda N; Hinotsu S; Shimozuma K; Akaza H; Ozono S
    Jpn J Clin Oncol; 2017 Jun; 47(6):551-559. PubMed ID: 28334974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world use of temsirolimus in Japanese patients with unresectable or metastatic renal cell carcinoma: recent consideration based on the results of a post-marketing, all-case surveillance study.
    Sugiyama S; Sato K; Shibasaki Y; Endo Y; Uryu T; Toyoshima Y; Oya M; Miyanaga N; Saijo N; Gemma A; Akaza H
    Jpn J Clin Oncol; 2020 Aug; 50(8):940-947. PubMed ID: 32458996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
    Motzer RJ; Escudier B; McDermott DF; George S; Hammers HJ; Srinivas S; Tykodi SS; Sosman JA; Procopio G; Plimack ER; Castellano D; Choueiri TK; Gurney H; Donskov F; Bono P; Wagstaff J; Gauler TC; Ueda T; Tomita Y; Schutz FA; Kollmannsberger C; Larkin J; Ravaud A; Simon JS; Xu LA; Waxman IM; Sharma P;
    N Engl J Med; 2015 Nov; 373(19):1803-13. PubMed ID: 26406148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study.
    Oudard S; Joly F; Geoffrois L; Laguerre B; Houede N; Barthelemy P; Gross-Goupil M; Vano Y; Lucidarme O; Bidault F; Kelkouli N; Slimane K; Escudier B
    Clin Genitourin Cancer; 2016 Dec; 14(6):e595-e607. PubMed ID: 27283478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
    Sternberg CN; Calabrò F; Bracarda S; Cartenì G; Lo Re G; Ruggeri EM; Basso U; Gasparini G; Ciuffreda L; Ferrari V; Bonetti A; Fea E; Gasparro D; Tassinari D; Labianca R; Masini C; Fly K; Zhang K; Hariharan S; Capaccetti B; Porta C
    Oncology; 2015; 88(5):273-80. PubMed ID: 25592399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.
    Choueiri TK; Escudier B; Powles T; Mainwaring PN; Rini BI; Donskov F; Hammers H; Hutson TE; Lee JL; Peltola K; Roth BJ; Bjarnason GA; Géczi L; Keam B; Maroto P; Heng DY; Schmidinger M; Kantoff PW; Borgman-Hagey A; Hessel C; Scheffold C; Schwab GM; Tannir NM; Motzer RJ;
    N Engl J Med; 2015 Nov; 373(19):1814-23. PubMed ID: 26406150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Granuloma-forming interstitial pneumonia occurring one year after the start of everolimus therapy.
    Saito Y; Kunugi S; Suzuki Y; Narita K; Miura Y; Minegishi Y; Kimura G; Kondo Y; Azuma A; Fukuda Y; Gemma A
    Intern Med; 2013; 52(2):263-7. PubMed ID: 23318860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes.
    Atkinson BJ; Cauley DH; Ng C; Millikan RE; Xiao L; Corn P; Jonasch E; Tannir NM
    BJU Int; 2014 Mar; 113(3):376-82. PubMed ID: 24053120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Rechallenge of everolimus for metastatic renal cell carcinoma after recovery from grade 3 interstitial lung disease: a case report].
    Utsunomiya N; Kono Y; Matsumoto K; Matsumoto T; Nakagawa A; Tsunemori H; Okada T; Muguruma K; Kawakita M
    Hinyokika Kiyo; 2014 Jan; 60(1):25-8. PubMed ID: 24594769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study.
    Thiery-Vuillemin A; Theodore C; Jacobasch L; Schmitz J; Papandreou C; Guillot A; Emmanouilides C; Slimane K; Kelkouli N; Kim S; Nguyen Tan Hon T
    Clin Genitourin Cancer; 2015 Jun; 13(3):231-8. PubMed ID: 25456838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.